The purpose of this study was to explore the relationship between cerebral amyloid deposition and overall clinical factors including cognitive functions in geriatric depression by using 18 F-florbetaben positron emission tomography. Thirteen subjects aged over 60 years who had a history of major depressive disorder and also had subjective memory complaint were included. Of all subjects, 3 subjects judged as amyloid positive, and the others judged as amyloid negative. Their memory, visuospatial functions and attention abilities were negatively correlated with amyloid deposition in specific brain regions, but their language and recognition abilities were not correlated with any region. The amyloid deposition of the whole brain region was significantly negatively correlated with immediate memory.
INTRODUCTION
Patients with geriatric depression (GD) often have subjective memory complaint (SMC), and patients in early stage of Alzheimer diseases (AD) also not seldom have depressive symptoms. [1] [2] [3] [4] There are many hypotheses about the correlation between GD and AD, but none of them can explain the causal relationship correctly. However, several recent studies have indicated that depression is associated with developing AD. [5] [6] [7] [8] Two meta-analyses reported that a history of depression increased the risk of developing AD, with the risk being approximately two times greater than that of the control group. 6, 8) The mechanisms linking depression and the risk of AD are unknown, but may involve abnormalities in multiple biological cascades, including the metabolism of -amyloid (A) peptide in the brain. 9, 10) The recent development of high-affinity positron emission tomography (PET) imaging ligands for A now permits the evaluation of the neuropathologic link among depression, cognitive impairment, and AD in vivo. 11) However, there are few studies that have examined cerebral A levels in GD until now.
Given this background, in this study, we aimed to explore the relationship between cerebral amyloid deposition in each brain region and the overall clinical factors including cognitive functions in GD by using amyloid PET.
METHODS

Participants
We studied a total of 13 subjects aged over 60 who had a history of major depressive disorder based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 12) They also had SMC, but had not been diagnosed with dementia yet. The exclusion criteria were a history of psychotic disorder including schizophrenia, other current clinically relevant neurologic illnesses, a history of apparent brain injury, or ever having undergone interventional treatments, including transcranial magnetic stimulation and electroconvulsive therapy.
All participants received clinical, psychological assessments, and were checked with 18 F-florbetaben (AV-1) PET at the same time. We assessed the cognitive functions 13)
The depressive symptom severity was evaluated based on the Hamilton Rating Scale for Depression (HAM-D). All participants were allowed to continue taking psychotropic drugs, but changes in medication were prohibited during the study period. The protocol of this study was approved by the institutional review board at Yeungnam University Hospital in Daegu, Korea (YUMC 2015-07-028-002).
Scanning and Imaging Procedure
All of the subjects received a single intravenous bolus of approximately 296 MBq (8 mCi) of 18 F-florbetaben. The PET scanner used was a Discovery 710 PET/CT system (GE Healthcare, Waukesha, WI, USA) in threedimensional acquisition mode. A continuous 20 minutes (min) brain PET data scan was acquired 90-min post injection and was reconstructed using 4 frames of 5-min each. Each subject also had an magnetic resonance imaging scan session, including a T1-weighted scan, which was employed for spatial normalization during voxelbased analysis.
Image Analysis
For the quantitative analysis of the 18 F-florbetaben PET images, we used the method of a previous study. 14) A region-of-interest (ROI) analysis was performed on the individual PET images, which were spatially normalized to the Montreal Neurological Institute (MNI) atlas space using Statistical Parametric Mapping 2.0 (SPM2; Wellcome Department of Imaging Neuroscience, Institute of Neurology, University College London). The mean cortical ROI templates contained 10 regions (frontal, temporal, occipital, parietal regions, basal ganglia [BG], cingulum, hippocampus, insula, amygdale and central region), as defined by the Automated Anatomic Labeling. 15) Mean cortical and whole cerebellar ROI templates were applied to all PET scans to calculate the mean regional cerebral-to-cerebellar standard uptake values (SUVRs).
14) The average of these regions was evaluated as a measure of the global mean cortical 18 F-florbetaben binding. A-positive (A＋) and A-negative (A−) 18 F-florbetaben PET statuses were defined according to the threshold of ≥1.10, a criterion derived from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.
16)
Statistical Analyses
The demographic and clinical characteristics between the A＋ and A− groups were compared by the MannWhitney U-test. The categorical data were analyzed using Fisher's exact test. The associations between the cerebral SUVRs and cognitive functions were evaluated using Pearson correlation coefficients. Significant correlations were validated using Spearman's rank correlations coefficients (Spearman's rho).
Statistical analyses were performed with the IBM SPSS Statistics ver. 22.0 statistical package (IBM Co., Armonk, NY, USA), and p values ＜0.05 were considered significant. Correlation is significant at the 0.01 level (2-tailed). Central region included precentral gyrus, postcentral gyrus and Rolondic operculum.
RESULTS
The demographic data and other clinical information are summarized in Table 1 . The sample included 13 subjects (mean age [SD]=72 [3. 98] years) including 7 females and 6 males. Ten subjects were judged as A− and 3 subjects as A＋. The sex, age, education level, depressive symptom severity and cognitive functions did not differ between the A− and A＋ groups. However, a first degree family history of AD was more prevalent in the A＋ group (p=0.038) and anxious distress specifier based on DSM-5 12) was more prevalent in the A＋ group (p= 0.033).
In the results of the correlation analysis (Table 2) On the other hand, the language functions, including naming and fluency, and recognition functions were not associated with any regional SUVRs.
DISCUSSION
In this study, we provide pilot data of amyloid PET in a sample of patients with GD and also with SMC. Most of the previous studies using amyloid PET focused on cerebral A in subjects with minor cognitive impairment (MCI) 17) or AD progression. However, there have been few studies which targeted subjects with GD. 9, 18, 19) Although we targeted subjects with GD, not AD, 3 subjects were assigned to the A＋ group. This implies that some of the GD subjects have significant accumulation of cerebral amyloid. However, the depressive symptoms or cognitive impairment of the A＋ subjects were not significantly different from those of the subjects with A−. This is because, in addition to the small sample size, all subjects had received a diagnosis of major depression, but its current severity varied. Therefore, the results of the cognitive function tests also varied, seemingly because they were affected by the current depressive symptoms. Most research on cognitive functions in patients with depression had found that depressed subjects tend to have worse performance. 20, 21) In one meta-analysis, there were significant associations between depression severity and some cognitive areas, including episodic memory, executive function and processing speed. 22) These complex interactions between depressive symptoms and cognitive impairment often make it difficult for the clinician to make an accurate diagnosis. However, it is important not to underestimate the possible role of cognitive impairment in GD.
All of the subjects in the A＋ group had been diagnosed with the anxious distress specifier, while only 1 subject in the A− group was so diagnosed. In the present study, the sample size is too small to show statistical significance, but there was a link with recent studies in which anxiety and irritability were significantly associated with greater amyloid deposition, 23) or the occurrence of dementia. 24) In addition, a first degree family history of AD was more prevalent in the A＋ group in this study. In similar previous studies, significant positive correlations were found in amyloid PET and FDG PET when there is a family history of AD. 25) Larger studies are needed for the purpose of replication.
In the results of the correlation analysis, memory, visuospatial functions and attention abilities were negatively correlated with amyloid deposition in specific brain regions. On the other hand, the language abilities, including naming and fluency, and recognition abilities were not associated with any regional SUVRs. Previous studies reported that the degree of episodic memory most accurately predicts future cognitive deterioration.
2) Moreover, language abilities are known to be a non-useful method of predicting the progression to AD.
26) The brain regions that showed significant associations in this study, including the insula, 27) hippocampus, 28) amygdale, 29) and BG, 30) are known to be related to specific cognitive functions which are usually found in AD or MCI.
While the results of this study are preliminary, they suggest that amyloid deposition in patients with GD is correlated with certain cognitive domains, which are known to be found in early dementia. Future large prospective studies will be able to address the relationship between the amyloid burdens as measured by amyloid PET and clinical factors including depression that may contribute to the manifestation of cognitive impairment and development of AD.
